Supplementary Materialsoncotarget-07-66512-s001
Supplementary Materialsoncotarget-07-66512-s001. in breast cancer cells treated with rottlerin. (C) Flow cytometry was used to detect the cell apoptosis in breast cancer cells treated with rottlerin. (D) Cell cycle was analyzed by Flow cytometry in rottlerin-treated breast cancer cells. Rottlerin induced cell apoptosis Previous studies have shown that rottlerin triggered apoptosis in breast cancer cells [17, 18]. We next aim to further validate whether cell proliferation inhibition by rottlerin treatment could be due to rottlerin-mediated cell apoptotic death. To this end, PI-FITC-annexin assay was performed to detect the cell apoptosis in both MCF-7 Picroside III and MDA-MB-231 cells treated with 3 M Rottlerin for 48 hours. We observed that rottlerin significantly induced cell apoptosis in both breast cancer cells (Figure ?(Figure1C).1C). Rottlerin treatment led to apoptotic cells from 5% to 13% in MCF-7 cells, and from 8.5% to 19% in MDA-MB-231 cells (Figure ?(Figure1C).1C). Consistent with other studies [17, 18], rottlerin could stimulate apoptosis in breast cancer cells. Rottlerin induced cell cycle arrest Next, we explored whether cell cycle arrest contributed to cell growth inhibition in breast cancer cells after rottlerin treatment. Cell cycle analysis by PI staining and flow cytometry in MCF-7 and MDA-MB-231 cells treated with different concentrations of rottlerin. Our results demonstrated that rottlerin treatment caused cell cycle arrest at G1 phase. Specifically, 3 M and 5 M rottlerin led to G1 cell population from 44% to 73.5% to 83%, respectively, in MCF-7 cells (Figure ?(Figure1D).1D). Similar result was found in MDA-MB-231 cells (Figure ?(Figure1D).1D). Our observations implied that rottlerin could induce G1 cell cycle arrest. Rottlerin inhibited cell migration and invasion To determine whether rottlerin inhibited cell Picroside III migratory activity, the wound healing Picroside III assay was conducted in MCF-7 and MDA-MB-231 cells treated with rottlerin. We found that rottlerin treatment remarkably suppressed cell migration in dose-dependent manner in both breast cancer cells (Figure ?(Figure2A).2A). To further define whether rottlerin has invasion inhibition potential, invasion assay was applied for measuring penetration of breast cancer cells via the matrigel-coated membrane. Our Transwell invasion assay revealed that rottlerin decreased the cell numbers of penetration through matrigel, suggesting that rottlerin could retard the cell invasion in breast cancer cells (Figure ?(Figure2B2B). Open in a separate window Shape 2 Aftereffect of rottlerin on cell migration and invasion(A) Best -panel: Wound curing assay was performed to detect the inhibitory aftereffect of rottlerin on MCF-7 cells and MDA-MB-231 cells after rottlerin treatment. Bottom level -panel: Quantitative email address details are illustrated for remaining -panel. ** 0.01 vs control (DMSO treatment). (B) Remaining -panel: Transwell chambers assay was carried out to measure the cell invasion in MCF-7 cells and MDA-MB-231 cells after rottlerin treatment. Right panel: Quantitative results are illustrated for left panel. ** 0.01 vs control. Rabbit polyclonal to KIAA0802 Rottlerin decreased Skp2 expression Skp2 has been characterized as an oncoprotein in breast cancer. Therefore, inhibition of Skp2 could be a promising approach for treating breast cancer. Next, we explored whether rottlerin could down-regulate Skp2 expression, leading to its anti-tumor activity in breast cancer cells. Real-time PCR and Western blotting were used to detect the expression of Skp2 at mRNA and protein levels, respectively, in breast cancer cells treated with rottlerin. The results showed that both Skp2 mRNA and its protein level were significantly decreased in rottlerin-treated cells (Physique 3A, 3B). We also found that the expression of p21, one of Skp2 downstream target, was upregulated in cells Picroside III after rottlerin treatment (Physique 3B and 3C). Our data validate that rottlerin inhibited Skp2 expression in breast cancer cells, indicating that rottlerin could function as a Skp2 inhibitor. Open in a separate window Physique 3 Rottlerin inhibited Skp2 expression at RNA and protein levels(A) RT-PCR was used to detect the Skp2 mRNA expression in breast.
